CTAP101 Capsules

DRUG4 trials

Sponsors

OPKO IP Holdings II, Inc., OPKO Health, Inc.

Conditions

Bone NeoplasmsBreast CancerChronic Kidney DiseaseChronic Renal FailureChronic Renal InsufficiencyHyperparathyroidism, SecondaryHypocalcemiaProstate Cancer

Phase 1

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

CompletedNCT00888069

OPKO IP Holdings II, Inc.Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Insufficiency +1

Start: 2009-05-31End: 2009-12-31Updated: 2014-09-30

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

CompletedNCT02274623

OPKO Health, Inc.Bone Neoplasms, Breast Cancer, Hyperparathyroidism, Secondary +2

Start: 2014-12-31End: 2017-03-17Updated: 2019-09-27

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

CompletedNCT03660800

OPKO Health, Inc.Secondary Hyperparathyroidism, Vitamin D Insufficiency

Start: 2018-08-20End: 2019-01-22Updated: 2019-09-30

Phase 3

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

CompletedNCT02282813

OPKO Health, Inc.Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency

Start: 2013-04-30End: 2015-05-31Updated: 2016-09-29